课题基金 / 基金详情

EFFICACY AND SAFETY OF MIBEFRADIL IN HYPERTENSION VERSUS LOSARTAN

EFFICACY AND SAFETY OF MIBEFRADIL IN HYPERTENSION VERSUS LOSARTAN
米贝拉地尔与氯沙坦治疗高血压的疗效和安全性
批准号：
6297156
负责人：
ALAN B WEDER
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6297156
关键词：
calcium channel blockers cardiovascular disorder chemotherapy clinical research dosage drug screening /evaluation human subject human therapy evaluation hypertension losartan vasodilators

项目摘要

项目成果

ALAN B WEDER的其他基金

相关文献

中文摘要
翻译
本研究的目的是评估米贝替拉迪和氯沙坦在积极治疗8周后平均坐下时舒张压（SDBP）测量值变化方面的差异。这项研究包括4周的安慰剂磨合期和8周的治疗期。在治疗期的前4周，患者接受米贝法地尔（50mg）或氯沙坦（50mg）。在第4周，对研究药物有反应的患者（平均SDBP<90mmHg）将继续以相同剂量使用相同的研究药物4周。在余下的4周至第8周内，平均SDBP低于90mm Hg的患者将滴定至最终剂量100mg，每天一次。
英文摘要
The objective of the current study is to evaluate the differnce between mibefradil and losartan in the change of mean trough sitting diastolic blood pressure (SDBP) measurements after 8 weeks of active treatment. This study includes a 4-week placebo run-in period followed by an 8-week treatment period. During the first 4 weeks of the treatment period, the patients receive either mibefadil (50mg), or losartan(50mg). At week 4, patients responding to the study drug, mean trough SDBP<90mmHg, will continue on the same study drug at the same dose for four more weeks. Patients with mean trough SDBP>90mm Hg, will titrate up to a final dose of 100 mg once daily for the remaining 4 weeks through weeek 8.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROXIMAL TUBULAR SODIUM REABSORPTION IN AFRICAN-AMERICANS AND WHITES
PROXIMAL TUBULAR SODIUM REABSORPTION IN AFRICAN-AMERICANS AND WHITES: A TUBULOC
GENETIC BASIS OF STROKE IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS
EFFICACY AND SAFETY OF MIBEFRADIL IN HYPERTENSION VERSUS LOSARTAN